Cargando…

P1313: PREDICTING OUTCOMES IN AML PATIENTS CONSOLIDATED BY AN ALLOGENEIC STEM CELL TRANSPLANTATION USING THE KNOWLEDGE BANK APPROACH

Detalles Bibliográficos
Autores principales:	Jentzsch, M., Herrmann, L., Bischof, L., Backhaus, D., Brauer, D., Franke, G.-N., Vucinic, V., Platzbecker, U., Schwind, S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430766/ http://dx.doi.org/10.1097/01.HS9.0000848116.66077.5d

Ejemplares similares

Impact of MRD status in patients with AML undergoing allogeneic stem cell transplantation in the first vs the second remission
por: Jentzsch, Madlen, et al.
Publicado: (2022)

P1356: PATIENT-SPECIFIC DIGITAL DROPLET PCR ASSAYS FOR MINIMAL RESIDUAL DISEASE DETECTION OF RUNX1 MUTATIONS IN ACUTE MYELOID LEUKEMIA PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION
por: Jentzsch, M., et al.
Publicado: (2022)

Risk Stratification, Measurable Residual Disease, and Outcomes of AML Patients with a Trisomy 8 Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
por: Backhaus, Donata, et al.
Publicado: (2021)

Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantation
por: Jentzsch, Madlen, et al.
Publicado: (2022)

PB2450: SEX-ASSOCIATED OUTCOME DIFFERENCES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
por: Ussmann, Jule, et al.
Publicado: (2023)

ELN risk stratification and outcomes in secondary and therapy-related AML patients consolidated with allogeneic stem cell transplantation
por: Jentzsch, Madlen, et al.
Publicado: (2020)

Clinical Implications of the FLT3-ITD Allelic Ratio in Acute Myeloid Leukemia in the Context of an Allogeneic Stem Cell Transplantation
por: Jentzsch, Madlen, et al.
Publicado: (2023)

P508: THE PROGNOSTIC SIGNIFICANCE OF THE MEASURABLE RESIDUAL DISEASE STATUS WITHIN THE THREE AML ELN2022 RISK GROUPS
por: Bischof, Lara, et al.
Publicado: (2023)

Impact of IDH1 and IDH2 mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation
por: Bill, Marius, et al.
Publicado: (2022)

A high hematopoietic cell transplantation comorbidity Index (HCT-CI) does not impair outcomes after non-myeloablative allogeneic stem cell transplantation in acute myeloid leukemia patients 60 years or older
por: Backhaus, Donata, et al.
Publicado: (2022)

P497: CLINICAL OUTCOMES OF NPM1-MUTATED ACUTE MYELOID LEUKEMIA (AML) PATIENTS WITH MEASURABLE RESIDUAL DISEASE (MRD) RELAPSE AFTER ACHIEVEMENT OF A FIRST MRD-NEGATIVE REMISSION
por: Jentzsch, Madlen, et al.
Publicado: (2023)

Nutritional Status at Diagnosis and Pre-transplant Weight Loss Impact Outcomes of Acute Myeloid Leukemia Patients Following Allogeneic Stem Cell Transplantation
por: Brauer, Dominic, et al.
Publicado: (2021)

Allogeneic stem cell transplantation mitigates the adverse prognostic impact of high diagnostic BAALC and MN1 expression in AML
por: Jentzsch, Madlen, et al.
Publicado: (2020)

P1315: THE CHRONOLOGICAL SEQUENCE OF 12 GY TOTAL BODY IRRADIATION AND CYCLOPHOSPHAMIDE CONDITIONING DOES NOT IMPACT OUTCOMES IN AML PATIENTS UNDERGOING MYELOABLATIVE ALLOGENEIC STEM CELL TRANSPLANTATION
por: Franke, Georg-Nikolaus, et al.
Publicado: (2023)

Measurable residual disease of canonical versus non-canonical DNMT3A, TET2, or ASXL1 mutations in AML at stem cell transplantation
por: Jentzsch, Madlen, et al.
Publicado: (2021)

Prognostic relevance of remission and measurable residual disease status in AML patients prior to reduced intensity or non-myeloablative allogeneic stem cell transplantation
por: Jentzsch, Madlen, et al.
Publicado: (2021)

P1381: EARLY FULL DONOR CHIMERISM AFTER FLAMSA RIC BASED ALLOGENEIC HSCT BUT NOT PRESENCE OF MORPHOLOGICAL REMISSION ASSOCIATES WITH OUTCOMES IN R/R AML PATIENTS
por: Ussmann, J., et al.
Publicado: (2022)

Case Report: Graft Versus Tumor Effect After Non-Myeloablative Allogeneic Stem-Cell Transplantation in a Patient With Brentuximab-Vedotin Refractory Sezary Syndrome
por: Franke, Georg-Nikolaus, et al.
Publicado: (2021)

High expression of the stem cell marker GPR56 at diagnosis identifies acute myeloid leukemia patients at higher relapse risk after allogeneic stem cell transplantation with the CD34(+)/CD38(-) population
por: Jentzsch, Madlen, et al.
Publicado: (2020)

Case Report: Allogeneic Stem Cell Transplantation Following Induction With CPX-351 in Patients With Acute Myeloid Leukemia Is Feasible
por: Vucinic, Vladan, et al.
Publicado: (2020)

The diagnostic red blood cell distribution width as a prognostic factor in acute myeloid leukemia
por: Vucinic, Vladan, et al.
Publicado: (2021)

Allogeneic Hematopoietic Stem Cell Transplantation in a Rare Case of Tonsillar Mast Cell Sarcoma
por: Kubasch, Anne Sophie, et al.
Publicado: (2020)

Salvage Therapy With Polatuzumab Vedotin, Bendamustine, and Rituximab Prior to Allogeneic Hematopoietic Transplantation in Patients With Aggressive Lymphomas Relapsing After Therapy With Chimeric Antigen Receptor T-Cells—Report on Two Cases
por: Gerhardt, Kristin, et al.
Publicado: (2021)

Outcomes of Older Patients with NPM1 Mutated and FLT3-ITD Negative Acute Myeloid Leukemia Receiving Allogeneic Transplantation
por: Jentzsch, Madlen, et al.
Publicado: (2020)

High BAALC copy numbers in peripheral blood prior to allogeneic transplantation predict early relapse in acute myeloid leukemia patients
por: Jentzsch, Madlen, et al.
Publicado: (2017)

Prognostic Impact of Blood MN1 Copy Numbers Before Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia
por: Jentzsch, Madlen, et al.
Publicado: (2019)

PB1768: MICRORNA SIGNATURES IMPLY A ROLE FOR FOXO IN AML CHEMO-RESISTANCE
por: Reichelt, Paula, et al.
Publicado: (2023)

Chromosome 12q13.13q13.13 microduplication and microdeletion: a case report and literature review
por: Hu, Jie, et al.
Publicado: (2017)

AML consolidation therapy: timing matters
por: Reimann, Adrian-Manuel, et al.
Publicado: (2023)

Precision oncology in AML: validation of the prognostic value of the knowledge bank approach and suggestions for improvement
por: Bill, Marius, et al.
Publicado: (2021)

Azacytidine impairs NK cell activity in AML and MDS patients undergoing MRD-based pre-emptive treatment after allogeneic stem cell transplantation
por: Schönefeldt, C, et al.
Publicado: (2013)

Clostridium thermocellum DSM 1313 transcriptional responses to redox perturbation
por: Sander, Kyle, et al.
Publicado: (2015)

Photoinduced Dynamics of 13,13′-Diphenylpropyl-β-carotene
por: Koo, Sangho, et al.
Publicado: (2023)

Bridging Strategies to Allogeneic Transplant for Older AML Patients
por: Hecker, Judith, et al.
Publicado: (2018)

MicroRNA Expression Patterns Reveal a Role of the TGF-β Family Signaling in AML Chemo-Resistance
por: Reichelt, Paula, et al.
Publicado: (2023)

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
por: Platzbecker, U, et al.
Publicado: (2012)

Pseudanabaena galeata CCNP1313—Biological Activity and Peptides Production
por: Cegłowska, Marta, et al.
Publicado: (2022)

13,13′-Bi(dibenzo[a,i]fluorenylidene)
por: Schollmeyer, Dieter, et al.
Publicado: (2022)

Genetic engineering of Clostridium thermocellum DSM1313 for enhanced ethanol production
por: Kannuchamy, Saranyah, et al.
Publicado: (2016)

A Rare Chromosomal Abnormality in Chronic Lymphocytic Leukemia: t(13;13)
por: Safaei, Akbar, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_l88u5au33hoo8ebkafbebktiit